読み込み中
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
前日終値
$4.02
+$0.02 · +0.50%
日中の時刻はETです。市場データは遅延する場合があります。
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
日中レンジ
現在 $4.02
52週レンジ
現在 $4.02
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
30
割高
センチメント
63
強気
リスク
52
やや高いリスク
モメンタム
59
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
日中レンジ
現在 $4.02
52週レンジ
現在 $4.02
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 368.6万 USD | 345.4万 USD | — | — | — |
| 粗利益 | −368.6万 USD | −345.4万 USD | — | — | — |
| 研究開発 | 1.85億 USD | 1.19億 USD | 1.14億 USD | 1.13億 USD | 1億 USD |
| 販売・一般管理 | 3170.9万 USD | 3462.5万 USD | 2802.1万 USD | 3094.6万 USD | 3064.7万 USD |
| 営業費用 | 2.13億 USD | 1.51億 USD | 1.44億 USD | 1.46億 USD | 1.31億 USD |
| 受取利息 | 971.7万 USD | 1587.3万 USD | 948.6万 USD | 365.2万 USD | 39万 USD |
| 減価償却費と償却費 | 216.6万 USD | 215万 USD | 214.8万 USD | 210.6万 USD | 214.1万 USD |
| 営業利益 | −2.16億 USD | −1.54億 USD | −1.44億 USD | −1.46億 USD | −1.31億 USD |
| 純利益 | −2.07億 USD | −1.38億 USD | −1.34億 USD | −1.42億 USD | −1.3億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2455.49万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2370.67万0.24%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1660.44万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF876.78万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO581.95万0.04%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB510万0.05%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO441.09万0.02%180億 USD0.06%$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM430.59万0.07%64.1億 USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
